MBX Biosciences, Inc. Common Stock Cash Flow-to-Debt Ratio
MBX Biosciences, Inc. Common Stock cash flow-to-debt ratio. MBX Biosciences, Inc. Common Stock (MBX) has a Cash Flow-to-Debt Ratio of -1.35x as of March 2026, meaning its operating cash flow of $-20.21 Million could theoretically repay -1% of its total liabilities ($14.95 Million) in one year. See MBX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of MBX Biosciences, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of MBX Biosciences, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for MBX Biosciences, Inc. Common Stock across 4 annual periods. Also explore how fast is MBX Biosciences, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
MBX Biosciences, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
MBX Biosciences, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for MBX Biosciences, Inc. Common Stock. For the full cash flow conversion analysis, see cash efficiency ratio of MBX Biosciences, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.02x | $-79.95 Million | $15.92 Million | ▼ -1.9% |
| 2024 | -4.93x | $-54.68 Million | $11.09 Million | ▼ -2314.7% |
| 2023 | -0.20x | $-31.98 Million | $156.65 Million | ▲ +22.6% |
| 2022 | -0.26x | $-23.12 Million | $87.70 Million | — |